ClinicalTrials.gg
CompletedNCT07142642Updated Feb 27, 2026

A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants

A Phase 1 interventional study of Teprotumumab and Placebo in Healthy Volunteers, sponsored by Amgen. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Amgen · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing teprotumumab in Graves Ophthalmopathy — 2 open to participants now, 3 under way, 1 of them phase 3. teprotumumab · Graves Ophthalmopathy.

Enrollment
11th of 12
20 · median 56
Started
2025
the only one that year
Phase 1
4 of 12
none open now
Registered
10th of 12
by date
Lead sponsor
10 of 12
Amgen

Among the 12 studies testing teprotumumab in Graves Ophthalmopathy, this one is the 11th largest by enrollment, is the only one that started in 2025, is one of 4 in phase 1, and was the 10th registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

2 of the 12 studies testing teprotumumab in Graves Ophthalmopathy are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About teprotumumab

teprotumumab: first FDA approval 2020 (TEPEZZA), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing teprotumumab in Graves Ophthalmopathy, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the pharmacokinetics (PK) of teprotumumab after a single intravenous (IV) infusion of teprotumumab in healthy Chinese participants.

03

Conditions studied

  • Healthy Volunteers

Browse trials for

Keywords

  • Pharmacokinetics
  • Healthy Chinese participants
  • Thyroid eye disease
  • TED
  • Thyroid-associated ophthalmopathy
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has provided .
  2. Participants must be a resident in mainland China, and of Chinese ancestry (participants whose parents within 3 generations are of Chinese ancestry).
  3. Male or female participants, between 18 and 60 years of age (inclusive). Female participants must be of nonchildbearing potential.
  4. In good health, determined by no findings from medical history, physical examination, 12-lead , vital signs measurements, and clinical laboratory evaluations.
  5. between 18 and 27 kg/m\^2 (inclusive) and minimum weight of 55 kg .

Exclusion criteria

Exclusion Criteria:

  1. History or evidence of disorder, condition, or disease.
  2. History of diabetes. (regardless of type with the exception of history of gestational diabetes). greater than or equal to 6.5% (greater than or equal to 48 mmol/mol).
  3. Fasting glucose level (after at least an 8-hour fast) > 126 mg/dL (> 7 mmol/L).
  4. History of or ongoing hearing impairment.
  5. History of any disease, inflammatory bowel disease, or TED.
  6. History or evidence of -findings.
  7. Systolic blood pressure ≥ 140 mmHg or \< 90 mmHg, or diastolic blood pressure ≥ 90 mmHg or \< 50 mmHg, or pulse > 100 bpm or \< 50 bpm , at screening or check-in.
  8. History of relevant drug and/or food allergies.
  9. Poor peripheral venous access and/or unable to receive IV infusion therapy.
  10. Estimated less than 90 mL/min/1.73 m2.
  11. Active liver disease or hepatic dysfunction.
  12. History of a medical condition associated with an increased risk of bleeding.
  13. History of any major surgery within 6 months.
  14. History of alcoholism or drug/chemical abuse within 1 year prior to check-in.
  15. Use of tobacco- or nicotine-containing products within 6 months prior to check-in.
  16. Positive test for illicit drugs and/or tetrahydrocannabinol/cannabinoids at check-in.
  17. Female participants with a positive serum pregnancy test.
  18. Female participants who are lactating/breastfeeding.
  19. Male participants with partners who are pregnant.
  20. Unwilling to adhere to requirements.
  21. Participant has received a dose of an drug within the past 90 days.
  22. Have previously completed or withdrawn from this study or any other study investigating teprotumumab or have previously received the investigational product.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Teprotumumab

    Participants will be randomized 3:1 to receive a single IV infusion of teprotumumab or placebo on Day 1.

    Drug: Teprotumumab

  • Placebo comparator
    Placebo

    Participants will be randomized 3:1 to receive a single IV infusion of teprotumumab or placebo on Day 1.

    Drug: Placebo

Interventions

  • Administered via IV infusion.

    Also known as: Tepezza, AMG 632

  • DrugPlacebo

    Administered via IV infusion.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of Teprotumumab

    Time frame: Up to Day 85

  2. Area Under the Serum Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Teprotumumab

    Time frame: Up to Day 85

  3. Area Under the Serum Concentration-time Curve From Time Zero to Infinity (AUCinf) of Teprotumumab

    Time frame: Up to Day 85

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events

    Time frame: Up to Day 85

  2. Number of Participants With Serious Adverse Events

    Time frame: Up to Day 85

  3. Number of Participants With Anti-teprotumumab Antibodies

    Time frame: Up to Day 85

07

Study locations

1 site
  • Huashan Hospital, Fudan University
    Shanghai, Shanghai Municipality 200040, China
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Nov 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2025
First posted
Aug 27, 2025
StartActual
Aug 26, 2025
Primary completionActual
Nov 22, 2025
CompletionActual
Jan 15, 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07142642
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 27, 2025
Start date
Aug 26, 2025
Primary completion
Nov 22, 2025
Completion
Jan 15, 2026
Last update
Feb 27, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teprotumumab

Start the discussion